ABCB1 and breast cancer: Long-term exposure to PARP inhibitor Olaparib has been shown to induce the overexpression of MDR1 and BCRP1, leading to drug resistance in mouse mammary tumours (Rottenberg et al., 2008), that could be reversed by pharmacological inhibition or deletion of MDR1 (Jaspers et al., 2013).